Treace Medical Concepts, Inc., headquartered in Ponte Vedra, Florida, is a publicly traded medical device company listed on NASDAQ under the ticker TMCI. Founded in 2014, the firm specialises in the surgical treatment of bunion and midfoot deformities, developing three-dimensional correction systems that address structural problems beyond the traditional two-dimensional surgical approach.
The company's product portfolio includes the Lapiplasty® 3D Bunion Correction® procedure, Adductoplasty®, IntelliGuide™ PSI, SpeedMTP®, Nanoplasty®, and Percuplasty™. These devices and procedures are designed to offer surgeons minimally invasive and reproducible outcomes for foot and ankle conditions. Operations include state-of-the-art facilities with Class 8 cleanrooms and additive manufacturing capabilities.
Treace maintains a worldwide geographic presence and has trained thousands of surgeons globally through its medical education programme, which features hands-on cadaveric training led by experienced surgeon faculty. The company's work is supported by an extensive body of peer-reviewed clinical studies in the field of foot and ankle orthopaedics.
